Healthcare review: Progenics & Salix Slump On FDA, pSivida & Vermillion Jump
(Thomson Reuters ONE) -
U.S. stocks turned lower after posting three straight gains with the DOW trading
down 15 points ahead of anticipated central-bank moves and the monthly jobs
report later in the week. Several healthcare stocks are making notable news at
mid day on Monday :-
Vermillion, Inc. (NASDAQ:VRML) stock gained 5.56% to $1.90 and traded much
higher one hour after the company announced positive results from a new
prospective, multi-center clinical study of its ovarian cancer diagnostic OVA1.
The study, referred to as OVA500, was led by Dr. Robert E. Bristow, director of
Gynecologic Oncology Services at UC Irvine Healthcare in Orange, CA, and deputy
editor of the journal Gynecologic Oncology.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) shares plunged -50.09% after the
company failed to gain U.S. approval to expand use of its constipation medicine
Relistor licensed to Salix Pharmaceuticals, Ltd.(NASDAQ:SLXP. The U.S. Food and
Drug Administration asked for more data about the treatment for opioid-induced
constipation in adult patients with chronic, non- cancer pain, the companies
said in a statement July 27. Shares of SLXP slid 12% to $46.81.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) stock declined -13.05% to $46.25 after
The FDA asked Salix Pharmaceuticals for more information regarding a drug
candidate. Salix and partner Progenics Pharmaceuticals, previously submitted a
request with the FDA for a broadened use of a drug called Relistor, which would
treat constipation in patients on pain medication.
Additionally, the shares of the company had its "buy" rating reaffirmed by
research analysts at Wells Fargo & Co. in a report released today.
pSivida Corp.(NASDAQ:PSDV) shares climbed as high as $3.24 and cloased at
$2.94+0.18 (6.52%) in the early hour after the company announced that it has
signed a funded technology evaluation agreement with a leading global
biopharmaceutical company to evaluate pSivida's Tethadur(TM) protein/antibody
delivery technology in the field of ophthalmology.
Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T), shares
traded as high as $0.58 but still managed to close up for the day at $0.54 Up
2.26%. The medical device developer of skin cancer detection systems continues
to gain traction in their bid to transform into a fully commercial venture.
Last week, the firm announced that they had accepted delivery of two initial
pre-production units of the Verisante Aura(TM), which will be used for final
usability and safety testing before commercial production begins by the end of
the year.
MWI Veterinary Supply, Inc. (NASDAQ:MWIV) stock surged to $107.26 but closed at
$97.08 +4.69 (5.08%) after the company posted third-quarter net income of $14.5
million, as against $11.4 million in the same quarter last year. Earnings per
share advanced to $1.15 from $0.91 in the same quarter a year ago. Total
revenues for the quarter improved 35% to $554.7 million. Analysts expected the
company to report earnings of $1.05 per share on revenues of $524.98 million for
the quarter.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Equity Briefing via Thomson Reuters ONE
[HUG#1630623]
Datum: 31.07.2012 - 05:21 Uhr
Sprache: Deutsch
News-ID 169978
Anzahl Zeichen: 3905
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 337 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Healthcare review: Progenics & Salix Slump On FDA, pSivida & Vermillion Jump"
steht unter der journalistisch-redaktionellen Verantwortung von
Equity Briefing (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
